Delayed chemokine receptor 1 blockade prolongs survival in collagen 4A3-deficient mice with Alport disease

被引:75
作者
Ninichuk, V
Gross, O
Reichel, C
Khandoga, A
Pawar, RD
Ciubar, R
Segerer, S
Belemezova, E
Radomska, E
Luckow, B
de Lema, GP
Murphy, PM
Gao, JL
Henger, A
Kretzler, M
Horuk, R
Weber, M
Krombach, F
Schlöndorff, D
Anders, HJ
机构
[1] Univ Munich, Med Poliklin, Nephrol Ctr, D-80336 Munich, Germany
[2] Univ Munich, Inst Surg Res, D-80336 Munich, Germany
[3] Univ Cologne, Fac Med, Dept Internal Med 1, Cologne Gen Hosp,Merheim Med Ctr, Cologne, Germany
[4] NIAID, Host Def Lab, NIH, Bethesda, MD 20892 USA
[5] Berlex Biosci, Dept Immunol, Richmond, CA USA
来源
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY | 2005年 / 16卷 / 04期
关键词
D O I
10.1681/ASN.2004100871
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Human Alport disease is caused by a lack of the alpha 3-, 4-, or 5-chain of type IV collagen (COL4A). Affected humans and COL4A3-deficient mice develop glomerulosclerosis and progressive renal fibrosis in the presence of interstitial macrophages, but their contribution to disease progression is under debate. This question was addressed by treating COL4A3-deficient mice with BX471, an antagonist of chemokine receptor 1 (CCR1) that is known to block interstitial leukocyte recruitment. Treatment with BX471 from weeks 6 to 10 of life improved survival of COL4A3-deficient mice, associated with less interstitial macrophages, apoptotic tubular epithelial cells, tubular atrophy, interstitial fibrosis, and less globally sclerotic glomeruli. BX471 reduced total renal Cll5 mRNA expression by reducing the number of interstitial CCL5-positive cells in inflammatory cell infiltrates. Intravital microscopy of the cremaster muscle in male mice identified that BX471 or lack of CCR1 impaired leukocyte adhesion to activated vascular endothelium and transendothelial leukocyte migration, whereas leukocyte rolling and interstitial migration were not affected. Furthermore, in activated murine macrophages, BX471 completely blocked CCL3-induced CCL5 production. Thus, CCR1-mediated recruitment and local activation of macrophages contribute to disease progression in COL4A3-deficient mice. These data identify CCR1 as a potential therapeutic target for Alport disease or other progressive nephropathies associated with interstitial macrophage infiltrates.
引用
收藏
页码:977 / 985
页数:9
相关论文
共 26 条
  • [1] Late onset of treatment with a chemokine receptor CCR1 antagonist prevents progression of lupus nephritis in MRL-Fas(lpr) mice
    Anders, HJ
    Belemezova, E
    Eis, V
    Segerer, S
    Vielhauer, V
    De Lema, GP
    Kretzler, M
    Cohen, CD
    Frink, M
    Horuk, R
    Hudkins, KL
    Alpers, CE
    Mampaso, F
    Schlöndorff, D
    [J]. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2004, 15 (06): : 1504 - 1513
  • [2] CC chemokine ligand 5/RANTES chemokine antagonists aggravate glomerulonephritis despite reduction of glomerular leukocyte infiltration
    Anders, HJ
    Frink, M
    Linde, Y
    Banas, B
    Wörnle, M
    Cohen, CD
    Vielhauer, V
    Nelson, PJ
    Gröne, HJ
    Schlöndorff, D
    [J]. JOURNAL OF IMMUNOLOGY, 2003, 170 (11) : 5658 - 5666
  • [3] A chemokine receptor CCR-1 antagonist reduces renal fibrosis after unilateral ureter ligation
    Anders, HJ
    Vielhauer, V
    Frink, M
    Linde, Y
    Cohen, CD
    Blattner, SM
    Kretzler, M
    Strutz, F
    Mack, M
    Gröne, HJ
    Onuffer, J
    Horuk, R
    Nelson, PJ
    Schlöndorff, D
    [J]. JOURNAL OF CLINICAL INVESTIGATION, 2002, 109 (02) : 251 - 259
  • [4] Halting the progression of chronic nephropathy
    Campbell, RC
    Ruggenenti, P
    Remuzzi, G
    [J]. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2002, 13 (11): : S190 - S195
  • [5] Collagen COL4A3 knockout: A mouse model for autosomal Alport syndrome
    Cosgrove, D
    Meehan, DT
    Grunkemeyer, JA
    Kornak, JM
    Sayers, R
    Hunter, WJ
    Samuelson, GC
    [J]. GENES & DEVELOPMENT, 1996, 10 (23) : 2981 - 2992
  • [6] Integrin α1β1 and transforming growth factor-β1 play distinct roles in Alport glomerular pathogenesis and serve as dual targets for metabolic therapy
    Cosgrove, D
    Rodgers, K
    Meehan, D
    Miller, C
    Bovard, K
    Gilroy, A
    Gardner, H
    Kotelianski, V
    Gotwals, P
    Amatucci, A
    Kalluri, R
    [J]. AMERICAN JOURNAL OF PATHOLOGY, 2000, 157 (05) : 1649 - 1659
  • [7] Multiple chemotactic factors: fine control or redundancy?
    Devalaraja, MN
    Richmond, A
    [J]. TRENDS IN PHARMACOLOGICAL SCIENCES, 1999, 20 (04) : 151 - 156
  • [8] Chemokine receptor CCR1 but not CCR5 mediates leukocyte recruitment and subsequent renal fibrosis after unilateral ureteral obstruction
    Eis, V
    Luckow, B
    Vielhauer, V
    Siveke, JT
    Linde, Y
    Segerer, S
    de Lema, GP
    Cohen, CD
    Kretzler, M
    Mack, M
    Horuk, R
    Murphy, PM
    Gao, JL
    Hudkins, KL
    Alpers, CE
    Gröne, HJ
    Schlöndorff, D
    Anders, HJ
    [J]. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2004, 15 (02): : 337 - 347
  • [9] Impaired host defense, hematopoiesis, guanulomatous inflammation and type 1-type 2 cytokine balance in mice lacking CC chemokine receptor 1
    Gao, JL
    Wynn, TA
    Chang, Y
    Lee, EJ
    Broxmeyer, HE
    Cooper, S
    Tiffany, HL
    Westphal, H
    KwonChung, J
    Murphy, PM
    [J]. JOURNAL OF EXPERIMENTAL MEDICINE, 1997, 185 (11) : 1959 - 1968
  • [10] Preemptive ramipril therapy delays renal failure and reduces renal fibrosis in COL4A3-knockout mice with Alport syndrome
    Gross, O
    Beirowski, B
    Koepke, ML
    Kuck, J
    Reiner, M
    Addicks, K
    Smyth, N
    Schulze-Lohoff, E
    Weber, M
    [J]. KIDNEY INTERNATIONAL, 2003, 63 (02) : 438 - 446